Mayne Pharma Group Valuation

Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Mayne Pharma Group last-minute Real Value cannot be determined due to lack of data. The latest price of Mayne Pharma Group is $0.0. Our model forecasts the value of Mayne Pharma Group from analyzing the firm fundamentals such as Profit Margin of (0.62) %, current valuation of 448.85 M, and Return On Equity of -0.41 as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend locking in undervalued stocks and disposing overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.

Mayne Pharma Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Mayne Pharma's current stock value. Our valuation model uses many indicators to compare Mayne Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mayne Pharma competition to find correlations between indicators driving Mayne Pharma's intrinsic value. More Info.
Mayne Pharma Group is considered to be number one stock in price to book category among related companies. It is considered to be number one stock in price to sales category among related companies fabricating about  0.90  of Price To Sales per Price To Book. The ratio of Price To Book to Price To Sales for Mayne Pharma Group is roughly  1.11 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Mayne Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Mayne Pharma's Pink Sheet . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mayne Pharma's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Mayne Pharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Mayne Pharma and how it compares across the competition.

About Mayne Pharma Valuation

The pink sheet valuation mechanism determines the current worth of Mayne Pharma Group on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Mayne Pharma Group. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Mayne Pharma Group based exclusively on its fundamental and basic technical indicators. By analyzing Mayne Pharma's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Mayne Pharma's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Mayne Pharma. We calculate exposure to Mayne Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Mayne Pharma's related companies.
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia. Mayne Pharma operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange.

8 Steps to conduct Mayne Pharma's Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Mayne Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Mayne Pharma's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Mayne Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Mayne Pharma's revenue streams: Identify Mayne Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Mayne Pharma's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Mayne Pharma's growth potential: Evaluate Mayne Pharma's management, business model, and growth potential.
  • Determine Mayne Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Mayne Pharma's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Mayne Pharma Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Mayne Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding1.8 B
Forward Price Earnings277.7778
Retained Earnings-822.4 M
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as various price indices.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Consideration for investing in Mayne Pink Sheet

If you are still planning to invest in Mayne Pharma Group check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mayne Pharma's history and understand the potential risks before investing.
CEOs Directory
Screen CEOs from public companies around the world
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Global Correlations
Find global opportunities by holding instruments from different markets
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios